FDA Has Approved Zealand Pharma ‘s Investigative New Drug Application (IND) for ZP1846 to Be Administered in Humans; ZP1846 Is Developed for the Prevention and Treatment of Severe Diarrhoea Induced by Chemotherapy

Zealand Pharma advances ZP1846 into Phase I clinical trials. ZP1846, a peptide which incorporates Zealand's proprietary SIP technology, is developed as a therapy for the prevention and treatment of chemotherapy-induced diarrhoea, a debilitating adverse reaction affecting patients undergoing treatment with many anti-cancer therapies.